Yongfeng Chen*, Xingjing Luo, Zhenyou Zou and Yong Liang Pages 1 - 22 ( 22 )
Reactive oxygen species (ROS) play a key role in tumorigenesis, tumor progression and recurrence. Recent findings have shown that ROS can be used to treat cancer as it accelerates death of tumor cells. At present, pro-oxidant drugs which are intended to increase ROS levels of the tumor cells have been widely used in clinic. However, ROS are a double-edged sword in the treatment of tumors. High levels of ROS induce not only tumor cell death but also oxidative damage to normal cells, especially bone marrow hemopoietic cells, which leads to bone marrow suppression and (or) other side effects, weakening efficacy of tumor treatment and even threatening patients’ life. How to enhance the killing effect of ROS on tumor cells while avoiding oxidative damage to the normal cells has become an urgent issue. This study is a review on the latest progress in the role of ROS-mediated programmed death in tumor treatment and prevention and treatment of oxidative damage in bone marrow induced by ROS.
ROS, programmed cell death, bone marrow protection, chemotherapy
Taizhou University hosipital, Taizhou University, Taizhou, 318000, Zhejiang, Taizhou University hosipital, Taizhou University, Taizhou, 318000, Zhejiang, Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, 541199, Guangxi, Taizhou University hosipital, Taizhou University, Taizhou, 318000, Zhejiang